No-Carrier-Added Lutetium-177 (n.c.a. Lu177) Archives

Tag: No-Carrier-Added Lutetium-177 (n.c.a. Lu177)

No-carrier-added Lutetium-177 displays superior characteristics when compared to the carrier-added analogue. The specific activity of n.c.a. Lutetium-177 is up to 4 to 5 times higher and offers the best preconditions for an efficient radiolabeling reaction. The n.c.a. Lu-177 product is characterized by a significantly longer shelf life than the c.a. Lu-177 variant, which must be used immediately upon receipt. Furthermore, n.c.a. Lutetium-177 provides the highest achievable radionuclidic purity. In comparison, c.a. isotope contains up to 0.1% metastable Lutetium-177m. This long-lived radionuclide decays with a half-life of 160.1 days and requires costly management and storage of contaminated radioactive waste and waste water.

29 Jan 2025

By Ronny Allan

4 Comments

Clinical Trial of PRRT ITM11 177Lu-Edotreotide – COMPETE for GEPNETs: Awaiting approval for GEPNETs (COMPETE) expected 28th Aug 2026

Clinical Trials and Research68Ga edotreotide (TOCscan®), Advanced neuroendocrine cancer, Afinitor, COMPETE trial, Edotreotide, EndolucinBeta, Everolimus, Gastro-entero-pancreatic neuroendocrine tumour (GEP-NET), Neuroendocrine cancer, Neuroendocrine tumour (NET), No-Carrier-Added Lutetium-177 (n.c.a. Lu177), Octreotide, Solucin ®, Somatostatin analogues, Somatostatin receptors (SSTR), TOCscan®

Update 4th July 2026. Data from the Phase 3 COMPETE trial - ITM11 [177Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early lines of therapy in patients with advanced, progressive GEP NETs. Bonus info about other trials for NET: 1. There is also an ITM11 product on trial for more aggressive G2/G3 GEPNETs known as COMPOSE - click here 2. An ITM11 product trial for Lung and Thymic NETs is running and currently in Phase 3 - known as LEVEL - Click here 3. A ITM11…